[Molecular Factors Related to Gefitinib Efficacy in Advanced Non-small Cell Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2010 Aug 3

PMID 20673523

Authors

Ping Lv

Tao Zhou

Affiliations

Soon will be listed here.

References

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Reck M . Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009; 9(4):401-12. DOI: 10.1586/era.09.1. View

Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S . Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005; 65(20):9176-84. DOI: 10.1158/0008-5472.CAN-05-1556. View

Giannelli G, Azzariti A, Fransvea E, Porcelli L, Antonaci S, Paradiso A . Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. Br J Cancer. 2004; 91(11):1964-9. PMC: 2409763. DOI: 10.1038/sj.bjc.6602231. View

Chan S, Gullick W, Hill M . Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer. 2005; 42(1):17-23. DOI: 10.1016/j.ejca.2005.07.031. View

Savinainen K, Linja M, Saramaki O, Tammela T, Chang G, Brinkmann A . Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer. 2004; 90(5):1041-6. PMC: 2409619. DOI: 10.1038/sj.bjc.6601648. View

Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M . Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg. 2001; 7(4):197-203. View

Fukai Y, Masuda N, Kato H, Fukuchi M, Miyazaki T, Nakajima M . Correlation between laminin-5 gamma2 chain and epidermal growth factor receptor expression in esophageal squamous cell carcinomas. Oncology. 2005; 69(1):71-80. DOI: 10.1159/000087477. View

Maheswaran S, Sequist L, Nagrath S, Ulkus L, Brannigan B, Collura C . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. PMC: 3551471. DOI: 10.1056/NEJMoa0800668. View

10.

Jiang H . Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol. 2008; 39(3):137-50. DOI: 10.1093/jjco/hyn139. View

11.

Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T . Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res. 2007; 67(16):7807-14. DOI: 10.1158/0008-5472.CAN-07-0681. View

12.

Zhang Z, Zhou C, Zhang J, Tang L, Su B . [Relationship between polymorphisms of DNA repair gene ERCC1 and susceptibility to lung cancer.]. Zhongguo Fei Ai Za Zhi. 2010; 11(2):183-8. DOI: 10.3779/j.issn.1009-3419.2008.02.022. View

13.

Konjevic G, Jurisic V, Jakovljevic B, SPUZIC I . [Lactate dehydrogenase (LDH) in peripheral blood lymphocytes (PBL) of patients with solid tumors]. Glas Srp Akad Nauka Med. 2005; (47):137-47. View

14.

Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S . Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 2007; 98(3):357-63. PMC: 11160083. DOI: 10.1111/j.1349-7006.2007.00387.x. View

15.

Han S, Kim T, Jeon Y, Hwang P, Im S, Lee K . Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res. 2006; 12(8):2538-44. DOI: 10.1158/1078-0432.CCR-05-2845. View

16.

Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T . Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer. 2005; 41(9):1286-90. DOI: 10.1016/j.ejca.2005.03.011. View

17.

Hirsch F, Varella-Garcia M, Bunn Jr P, Franklin W, Dziadziuszko R, Thatcher N . Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24(31):5034-42. DOI: 10.1200/JCO.2006.06.3958. View

18.

Cappuzzo F, Magrini E, Ceresoli G, Bartolini S, Rossi E, Ludovini V . Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004; 96(15):1133-41. DOI: 10.1093/jnci/djh217. View

19.

Dubey S, Stephenson P, Levy D, Miller J, Keller S, Schiller J . EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol. 2007; 1(5):406-12. View

20.

Cappuzzo F, Varella-Garcia M, Rossi E, Gajapathy S, Valente M, Drabkin H . MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. J Thorac Oncol. 2009; 4(4):472-8. PMC: 2774779. DOI: 10.1097/JTO.0b013e31819a5767. View